Company Profile

  1. You are here:    Home
  2. Search Databases
  3. Search Company Registry
  4. Company Profile

ADT Pharmaceuticals Inc
Profile last edited on: 6/10/20      CAGE: 7BX76      UEI: YL5LNM35E194

Business Identifier: Lung cancer research
Year Founded
2014
First Award
2015
Latest Award
2019
Program Status
Active
Popularity Index

Edit Company Profile

Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.
  Explanation Edit

Location Information

31691 Shoalwater Drive
Orange Beach, AL 36561
   (251) 786-4527
   N/A
   www.adtpharma.com
Location: Single
Congr. District: 01
County: Baldwin

Public Profile

Google listing for this firm has it indicated as having closed its doors.

Extent of SBIR involvement

User Avatar
Phase I Awards
5
Phase II Awards
0
Conversion Rate
0.00%
Phase I Dollars
$1,424,805
Phase II Dollars
$2,000
Total Awarded
$1,426,805

Synopsis: Awardee Business Condition

Employee Range
1-4
Revenue Range
Less than .5M
VC funded?
No
Public/Private
Privately Held
Stock Info
----
IP Holdings
20-24

Awards Distribution by Agency

Most Recent SBIR Projects
Year Phase Agency Total Amount
2019 1 NIH $299,963
Project Title: Novel Orally Bioavailable Pde -Catenin Inhibitor Concentrates In Lung For Cancer Chemoprevention
2019 1 NIH $299,963
Project Title: Novel Orally Bioavailable PDE -Catenin Inhibitor Concentrates in Lung for Cancer Chemoprevention
2018 1 NIH $302,000
Project Title: Oral formulation for novel inhibitor of Ras driven cancers
2016 1 NIH $300,000
Project Title: Novel Ras Inhibitor Prodrug for Colorectal Cancer
2015 1 NIH $224,879
Project Title: A Novel Phosphodiesterase Isozyme Target and Class of Inhibitors for Lung Cancer

Key People / Management

  Michael R Boyd -- Co-Founder and President

  Joshua Canzoneri

Company News

There are no news available.